AXIM - AXIM Biotechnologies, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

AXIM Biotechnologies, Inc.

5 Rockefeller Plaza
20th Floor
New York, NY 10111
United States

Full Time Employees6

Key Executives

Dr. George E. Anastassov M.D., DDS, MBAChairman, CEO & Pres955.62kN/A54
Mr. Lekhram ChangoerCTO & Director818.2kN/A50
Dr. Philip A. Van Damme DMD, MD, Ph.D.Chief Scientific Officer & Director54kN/A64
Mr. Robert T. MalasekCFO & Sec.N/AN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AXIM Biotechnologies, Inc., a biotechnology company, focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is based in New York, New York.

Corporate Governance

AXIM Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.